Parkinson's: positive CHMP opinion for a levodopa/carbidopa formulation

This morning’s Health section was occupied by an epidemiological study on passive smoking. This piece concerns a different story: a European regulatory decision, and the distance between what such a decision states and what corporate press releases attribute to it.

At its meeting of 22-25 June 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency, the CHMP, recommended granting marketing authorisation for Hopledo, a formulation based on levodopa and carbidopa. The indication concerns adults with Parkinson’s disease and moderate to severe motor fluctuations who are not adequately stabilised on oral regimens of levodopa and dopa-decarboxylase inhibitors. The outcomes of the meeting are published by the European Medicines Agency.

What the procedure states

The institutional point is the pathway followed. Centralised authorisation granted at European level allows access to the twenty-seven national markets of the Union without repeating regulatory procedures country by country. It is an administrative simplification, not an additional clinical judgment: the committee’s recommendation concerns the benefit-risk balance assessed on the dossier submitted, and does not establish either timelines or reimbursement conditions, which remain decisions of individual States.

What the company states, and how it should be read

According to the company holding the authorisation, the approval is based on the phase 3 study called RISE-PD, which is said to have shown an increase in time with symptoms under control — referred to in the company communication as “Good ON” time — with fewer daily administrations compared with the traditional formulation. The communication is reported in the roundup by Europeisti.

This newspaper reports it for what it is: the position of the party that benefits from it. The limitations to be stated are explicit. The available sources do not indicate the sample size of the study, nor its duration, nor its experimental design, nor any conflicts of interest declared in the publication. There is no independent evaluation of those results available in the material at hand: the regulatory committee’s document attests to the recommendation, it does not replicate the company’s data on the extent of the benefit. A phase 3 study is the stage that precedes the authorisation request, not a measure of efficacy under real-world conditions of use.

The company indicates a gradual rollout across European markets starting from October 2026 and reports that the product is already marketed in the United States under a different trade name. These too are statements from the party concerned, not regulatory commitments.

The second appointment: the flu vaccination campaign

On the Italian public health front, the Ministry of Health’s circular on influenza for 2026-2027 provides for the vaccination campaign to start at the beginning of October, corresponding to the fortieth week of the year. Organisational preparation is under way, with the definition of vaccination sites, communication, and dose distribution. The documentation is gathered by the EpiCentro portal of the Istituto Superiore di Sanità, which also accounts for the step upstream: which strains should go into the preparations intended for the northern hemisphere for the coming season is an indication from the World Health Organization, made known on 27 February 2026. The ministerial circular is also reported in the roundup by Torrinomedica.

The technical reason for the annual update of the strains is indicated in the same sources: influenza viruses continually evolve, and the periodic revision of the composition serves to maintain the effectiveness of the preparations.

What we do not know

We do not know in which Member States and on what timeline Hopledo will actually be available, nor under what reimbursement conditions: the committee’s recommendation does not contain this information. The numerical data of the RISE-PD study are not available in the sources used. Regarding the Italian flu vaccination campaign, the target categories for the offer and the quantities of doses purchased have not yet been published.